Skip to content
Biodatica
Start free

Investigator

M Javad Aman

ABVACC, INC. · funded by NIAID

Companies
2

Resolved onto their grants.

Grants
6

Federal awards on file.

Non-dilutive funding
$4.9M

Summed across those awards.

First award
Aug 1, 2014

Latest Aug 22, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R01

    A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia

    $639k

    Aug 22, 2025NIAIDABVACC, INC.NIH RePORTER · 11204972 (opens the source filing in a new tab)

  2. R44

    Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease

    $1.0M

    Aug 11, 2023NIAIDABVACC, INC.NIH RePORTER · 11261287 (opens the source filing in a new tab)

  3. R44

    Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease

    $1.0M

    Aug 11, 2023NIAIDABVACC, INC.NIH RePORTER · 11337576 (opens the source filing in a new tab)

  4. R44

    Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control

    $915k

    May 12, 2023NIAIDABVACC, INC.NIH RePORTER · 11077219 (opens the source filing in a new tab)

  5. R01

    Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease

    $646k

    Aug 1, 2014NIAIDABVACC, INC.NIH RePORTER · 11062448 (opens the source filing in a new tab)

  6. R01

    Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease

    $697k

    Aug 1, 2014NIAIDABVACC, INC.NIH RePORTER · 11285431 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources